Editas Medicine (EDIT) CFO receives grant of 292,856 stock options

Rhea-AI Filing Summary

Editas Medicine, Inc. reported that its SVP and Chief Financial Officer, Amy Parison, received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and were granted as a compensation award, not an open-market purchase.

According to the disclosure, the options were granted on March 12, 2026 and are scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this award, she holds 292,856 option-based rights to acquire Editas Medicine common shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parison Amy

(Last) (First) (Middle)

11 HURLEY STREET

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.54	03/12/2026		A		292,856		(1)	03/11/2036	Common Stock	292,856	$0	292,856	D

Explanation of Responses:

1. This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030.

Remarks:

	/s/ Amy Parison	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Editas Medicine (EDIT) report for Amy Parison?

Editas Medicine reported that CFO Amy Parison received a grant of stock options for 292,856 shares. The award is a compensation grant, not an open-market trade, giving her the right to buy common stock at a fixed exercise price.

How many Editas Medicine (EDIT) shares are covered by Amy Parison’s new stock options?

The new stock option grant to CFO Amy Parison covers 292,856 shares of Editas Medicine common stock. These options provide potential future share ownership if exercised, subject to the vesting schedule and the stated exercise price.

What is the exercise price of Amy Parison’s Editas Medicine (EDIT) stock options?

The stock options granted to Amy Parison carry an exercise price of $2.54 per share. This means she can buy Editas Medicine common stock at that price once the options vest and she chooses to exercise them.

How do Amy Parison’s Editas Medicine (EDIT) stock options vest over time?

The options granted to Amy Parison vest in equal monthly installments over four years. Vesting begins on April 12, 2026 and continues through March 12, 2030, gradually increasing the portion of the award she can exercise.

When do Amy Parison’s Editas Medicine (EDIT) stock options expire?

The granted stock options are scheduled to expire on March 11, 2036. After this expiration date, any unexercised options will lapse, so potential value depends on vesting and Editas Medicine’s share price before that time.

Is Amy Parison’s Editas Medicine (EDIT) Form 4 transaction a purchase or a grant?

The Form 4 shows a grant or award acquisition of stock options, not an open-market purchase. The options were issued as compensation with no cash paid at grant, giving her the right to buy shares later at $2.54 per share.